
Clerk of the House of Representatives Legislative Resource Center B-106 Cannon Building Washington, DC 20515

Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510



02 FEB -14 PM 2: 23

## **LOBBYING REPORT**

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required To Complete This Page

1. Registrant Name	·
Stuntz, Davis & Staffier, P.C.	
2. Address Check if different than previously reported	
1275 Pennsylvania Avenue, N.W. 9th Floor	
3. Principal Place of Business (if different from line 2)	
City: Washington State/Z	tip (or Country) DC 20004
4. Contact Name Telephone	E-mail (optional) 5. Senate ID#
Randall E. Davis (202) 662-6790	37141
7. Client Name Self	6. House ID #
Pharmaceutical Research and Manufacturers of Americ	a 30970
O. Check if this filing amends a previously filed version of this in the content of the content	Date 11. No Lobbying
12. Lobbying Firms	13. Organizations
INCOME relating to lobbying activities for this reporting period was:	EXPENSES relating to lobbying activities for this report period were:
Less than \$10,000 -	Less than \$10,000 🚨
\$10,000 or more  \$\simeq\$ \$\frac{\\$20,000.00}{\\$\lncome\\$ (nearest \$20,000)}\$  Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).	\$10,000 or more  Expenses (nearest \$20,00  14. REPORTING METHOD. Check box to indicate accounting method. See instructions for description of  Method A. Reporting amounts using LDA definiti  Method B. Reporting amounts under section 6033
	Internal Revenue Code  Method C. Reporting amounts under section 162( Internal Revenue Code
Printed Name and Title	

Registrant Name Stuntz, Davis & Staffier, P.C. Client N	Name Pharmaceutical Research and Manufacturers of Ar
LOBBYING ACTIVITY. Select as many codes as necess engaged in lobbying on behalf of the client during the repo information as requested. Attach additional page(s) as need	rting period. Using a separate page for each code
15. General issue area code PHA (one per page)	
16. Specific lobbying issues	
Relaxation of drug import standards, including proposed ame Appropriations legislation, H.R. 2330. Reauthorization of Pre Pharmaceuticals for Children Act": extension of pediatric excl	scription Drug User Fee Act. H.R. 2887, "Best
17. House(s) of Congress and Federal agencies contacted	Check if None
U.S. House of Representatives	
18. Name of each individual who acted as a lobbyist in thi	s issue area
Name	Covered Official Position (if applicable)
Randall E. Davis	
	,
<u> </u>	
*	
19. Interest of each foreign entity in the specific issues listed on	line 16 above
Signature Kandsell Cours	Date 2/14/02
Printed Name and Title Randall E. Davis, President	